APO-MEMANTINE 10 MG
MEMANTINE HYDROCHLORIDE : 10 MG · DIN 02366487 · APOTEX INC
Health Canada status: MARKETED
What is APO-MEMANTINE?
APO-MEMANTINE 10 MG contains MEMANTINE HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02366487, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 25-May-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-MEMANTINE used for?
Monotherapy for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer’s type.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02366487 |
|---|---|
| Brand name | APO-MEMANTINE |
| Generic / active ingredient | MEMANTINE HYDROCHLORIDE : 10 MG |
| Manufacturer | APOTEX INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06DX01 MEMANTINE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-May-2020 |
How is it administered?
Initial: 5 mg/day, increased weekly by 5 mg/day to a target of 20 mg/day (10 mg twice a day). Adjust for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text.
How is it supplied?
Not explicitly detailed in provided text (mentions 10 mg tablets).
Contraindications
Hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.
Warnings and precautions
Caution in patients with seizure disorders, cardiovascular conditions, or conditions that raise urine pH. Risk of serious skin reactions and ophthalmic changes.
Is MEMANTINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06DX01 MEMANTINE. 9 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT MEMANTINE | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02324067 |
| MEMANTINE | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02446049 |
| MEMANTINE | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02443082 |
| MINT-MEMANTINE | 10 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02531887 |
| PMS-MEMANTINE | 10 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02321130 |
| PMS-MEMANTINE | 5.0 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02382830 |
| RIVA-MEMANTINE | 10 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 02348950 |
| SANDOZ MEMANTINE FCT | 10 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02375532 |
| ACT MEMANTINE | 5 MG | TABLET | TEVA CANADA LIMITED | APPROVED | DIN 02324059 |
| EBIXA | 10 MG | TABLET | LUNDBECK CANADA INC | CANCELLED POST MARKET | DIN 02260638 |
Who else supplies MEMANTINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MEMANTINE appears in 278 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.